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In this issue of the JCI, Panigrahy et al. demonstrate that preoperative administration of the
antiinflammatory drug ketorolac or specialized proresolving mediators (SPM) called
resolvins increases disease-free survival rates and prevents metastasis after surgery and
chemotherapy in mouse models of cancer. The antitumor response was partially mediated
by tumor-specific T cell immunity and immunological memory.
Commentary
Find the latest version:
http://jci.me/129705/pdf
The Journal of Clinical Investigation   C OMM E N TA RY
1jci.org
Dampening the fire to prevent surgery- and 
chemotherapy–induced metastasis
Esra Güç and Jeffrey W. Pollard
MRC Centre for Reproductive Health, Queen’s Medical Research Institute, The University of Edinburgh, Scotland, United Kingdom.
When treatment also promotes 
disease
A century after Virchow hypothesized the 
association between inflammation and can-
cer, it is becoming evident that inflamma-
tory mediators lead to cancer progression 
and metastasis (1). Surgical incision– and 
chemotherapy-induced immune response 
has been known to enhance tumor-antigen 
recognition by T cells, yet paradoxically, the 
tumor killing mediates the release of acute 
inflammatory cytokines and prostaglan-
dins, which helps tumor dissemination and 
metastasis (2, 3). Moreover, although neo-
adjuvant and adjuvant chemotherapy are 
the most potent methods for cancer treat-
ment, both clinical and experimental stud-
ies suggest that chemotherapy can induce 
the incidence of premetastatic niche forma-
tion by increasing the release of inflamma-
tory factors and extracellular vesicles from 
the primary tumor as well as awakening 
dormant metastasized cells (4–6).
Prostaglandins and leukotrienes 
are actively produced lipids in chronic 
inflammation and cancer. Cyclooxy-
genase-2–mediated (COX-2–mediated) 
prostaglandin E2 (PGE2) production is 
increased during tumorigenesis, and its 
secretion is induced by several immune 
cells, including macrophages and neu-
trophils (7). Epidemiologic and clinical 
metaanalysis provides strong evidence 
that the use of COX-2–selective or COX-1/ 
COX-2–inhibiting NSAIDs increases 
disease-free survival rate and reduces 
cancer recurrence (8, 9). Nevertheless, 
this association is not established for all 
types of cancer, and especially, the che-
mopreventive role of NSAIDs remains 
controversial because of the toxicity 
caused by long-term inhibition of COX 
and prostaglandins (10, 11). The antitu-
moral role of COX-1–inhibiting NSAIDs 
is less well studied, since this pathway 
is not overexpressed during tumor pro-
gression and it plays an important role in 
homeostasis (12).
Preoperative inflammation 
inhibition increases 
metastasis-free survival
In this issue of the JCI, a new study by Pan-
igrahy and colleagues brings a different per-
spective on the role of the COX-1 pathway in 
cancer therapy (13). The study addresses the 
paradoxical finding that surgery and chemo-
therapy, while often effective therapeutically, 
can also lead to an increase in metastasis, a 
finding that has been attributed to inflam-
matory responses. The authors first demon-
strate how surgical trauma and chemothera-
py applied to tumors that are at or below the 
threshold of growth enhanced tumor escape 
as well as metastasis. Inhibition of inflamma-
tion by the administration of a potent NSAID 
ketorolac, when given preoperatively but not 
postoperatively, increased metastasis-free 
survival. Similar results were obtained with 
their use in chemotherapy.
To better understand whether this 
effect was selective to COX-1 inhibition, the 
authors tested various COX-1, COX-2, and 
COX-1/2 inhibitors including some of the 
commonly used NSAIDs, such as indometh-
acin, aspirin, and ibuprofen. These studies 
indicated that COX-1 inhibitors, but not 
COX-2 selective inhibitors, induced an anti-
tumor effect when applied at the preopera-
tive stage. Interestingly, the authors demon-
strated that the effects of COX-1 inhibition 
were diminished when the COX-2 pathway 
and prostaglandin (PGE2) production were 
blocked in the Lewis lung carcinoma (LLC) 
model. Thromboxane A2 (TXA2) down-
stream from COX-1 is a potent vasoconstric-
tor and induces platelet aggregation, a pro-
cess that is known to help metastatic tumor 
seeding and cancer cell survival in mouse 
models. Preoperative ketorolac decreased 
TXA2 production, and administration of 
a TXA2 inhibitor also showed antitumor 
effects similar to those of ketorolac, suggest-
ing that targeting this pathway as precancer 
treatment might be important in preventing 
metastatic seeding (Figure 1).
Although Serhan and his group 
described the role of resolvins and lipoxins 
in the resolution of inflammation in 2002 
(14), little is known about their functions 
in cancer inflammation. Yet administering 
resolvins as a cancer treatment provides 
significant improvement. A recent study 
by Panigrahy et al. explored this mecha-
nism and showed that resolvins enhance 
the debris-cleaning function of macro-
phages and prevent cell-mediated inflam-
matory response and tumor progression 
(15). Similarly, in this current paper, pre-
operative resolvin administration drasti-
cally prolonged tumor-free survival after 
tumor resection. However, whether this 
result is correlated with resolvin-mediated 
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number of T cells in the spleen after tumor 
resection. Gene ontology of T cell clusters 
suggested that ketorolac helps to rescue T 
cell exhaustion and increase the number of 
memory T cells. Although a drastic change 
in the B cell population was detected after 
ketorolac treatment, the role of B cells in 
developing immunological memory was 
not explored. This group also performed 
a more comprehensive analysis of Ly6G+ 
granulocytes and showed that this pop-
ulation is decreased in ketorolac-treated 
mice concurrent with decreased MMP-9, 
NF-κB, and PI3K activation. These genes 
are associated with protumoral granulo-
cytes that suppress T cell proliferation and 
antitumor immunity. Together, these data 
strongly suggest that granulocytic immu-
nosuppression was removed by ketorolac.
This study is valuable in terms of under-
standing the impact of NSAIDs on cancer 
treatment. Importantly, it emphasizes the 
need to understand biological responses 
to inflammation that can be protumoral in 
drastically increasing in mice adminis-
tered such combination therapy.
Furthermore, ketorolac also mediat-
ed immunological memory. Months after 
tumor resection, ketorolac-treated mice 
rechallenged with the same tumor cell type 
rejected those cells; however, this effect was 
tumor specific, indicating the acquisition of 
immunity. Adoptive CD8+ T cell transfer 
from this group of tumor-challenged mice 
into naive mice also gave them antitumor 
immunity to the comparable tumor type. 
This finding is striking and highlights that 
short-term NSAID administration just 
before surgical incision affects the long-
term antitumor immune responses.
To investigate this phenomenon fur-
ther, the authors performed single-cell 
transcriptomic analysis of splenic immune 
cells seven days after the surgical incision. 
While the depth of sequence and analy-
sis was relatively slight, the results con-
firmed their previous histological analysis 
and showed that ketorolac increased the 
debris cleaning or through the resolution 
of inflammation and how this affects the 
prometastatic infiltration of inflammatory 
monocytes in metastatic organs are open 
questions that should be investigated in 
future studies.
The authors investigated how ketoro-
lac and resolvins might act by examining 
the role of splenic antitumor immune 
responses. Preoperative administration 
of ketorolac increased splenic CD4+ and 
CD8+ T cells, whereas Foxp-3, a marker 
of T regulatory cells, was decreased. Pre-
vious studies targeting the COX-2 path-
way and PGE2 production also demon-
strated a reduction of CD4+Foxp-3+ T 
cells (16, 17), suggesting that both COX-1 
and COX-2 inhibition targets immuno-
suppressive tumor mechanisms. The 
authors also showed that the antitumor 
effect of ketorolac is T cell dependent. 
Importantly, ketorolac acts synergistical-
ly with the immune checkpoint inhibitor, 
anti-PD1 antibody, with survival rates 
Figure 1. Surgical excision and chemotherapy induce inflammation-mediated metastasis in mouse models of cancer that can be blocked with ketorolac 
and resolvins. Preoperative administration of the antiinflammatory NSAID ketorolac and the SPM called resolvin increases disease-free survival rates and 
prevents metastasis in mouse tumor models. Ketorolac inhibits the COX-1 pathway and formation of platelet aggregation by blocking TXA2 production. 
COX-2/PGE2 activity is required when ketorolac is administered preoperatively. Ketorolac also increases the production of an SPM called lipoxin A (LXA4) 
that plays a role in the antitumor function of ketorolac. Resolvins are produced from omega-3 fatty acid metabolism; however, in this study, resolvins were 
exogenously administered at the preoperative stage and increased cancer-free survival in mouse models. Preoperative ketorolac administration increased 
CD4+ and CD8+ T cells and immunological memory, decreased Foxp3+ regulatory T cells, and exhausted T cells in the spleen. These immunological changes 
mediate the antitumor action of this inhibitor. PGs, prostaglandin E2, D2 and F2 alpha; PGI2, prostacyclins; LOX, lipoxygenase; EPA, eicosapentaenoic acid; 
DHA, docosahexaenoic acid.
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fascinating to understand the mechanisms 
of the response in light of other recent 
observations in this area. For example, 
studies have shown that chemotherapeutic 
stress on cancer cells induces the produc-
tion of microvesicles that prime premeta-
static sites (5). Are the beneficial effects of 
resolvins and ketorolac mediated by the 
resolution of inflammation and subsequent 
blocking of microvesicle formation and/or 
cancer cell homing or are they solely medi-
ated through effects on immune cells that 
kill metastatic tumor cells?
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order to effectively suppress it. In addition, 
this study emphasizes the need for the cor-
rect timing required to inhibit such inflam-
matory responses to have a therapeutic 
impact. It also suggests that standard-of-
care treatments with the appropriate antiin-
flammatory reagents might unleash a T cell 
response that ablates dormant metastatic 
cells and micrometastases. If this can be 
translated from mouse models into the clin-
ic, then it could revolutionize treatments. 
Notably, the COX-2 pathway ameliorated 
the effect of ketorolac, indicating the need 
for correct combinations of COX-1/COX-2 
inhibitors even within this NSAID class.
Conclusions and remaining 
questions
While an important first step, this study 
leaves many unanswered questions that will 
need to be investigated before moving from 
mouse models to clinical trials. Foremost 
among these is the sole use of xenografted 
cancer models that are highly immuno-
genic and injected subcutaneously. While 
this system is a proof of principle, these 
are not true autochthonous cancers that 
are heterogeneously evolving structures 
with complex and continuously changing 
microenvironments. In addition, it needs to 
be established how resolvins and ketorolac 
launch the antitumoral immune response 
and how these molecules rescue exhaust-
ed T cells and synergize with anti-check-
point inhibitors. At present, the changes in 
immune cells in this study were analyzed 
only at low resolution from the spleen, but 
not lymph nodes or target tissues, so studies 
in greater depth are in order. It will also be 
